In the experimental setting with robust neprilysin overexpression (~8-fold), it seems difficult to unequivocally demonstrate the advantage of combining partial BACE1 inhibition and neprilysin upregulation in further facilitating their beneficial outcomes during advanced stages of AD. Here, BACE1 is linked to Alzheimer disease.